Patterns of discordance between pretransplant imaging stage of hepatocellular carcinoma and posttransplant pathologic stage: A contemporary appraisal of the milan criteria

Brett L. Ecker, Maarouf A. Hoteit, Kimberly A. Forde, Christine C. Hsu, K. Rajender Reddy, Emma E. Furth, Evan S. Siegelman, Peiman Habibollahi, Edgar Ben-Josef, Paige M. Porrett, Peter L. Abt, Abraham Shaked, Kim M. Olthoff, Matthew H. Levine

Research output: Contribution to journalArticle

8 Scopus citations


Background Patients with hepatocellular carcinoma (HCC) exceeding Milan criteria on explant pathology are at increased risk of recurrence and death. Discordance between contemporary magnetic resonance imaging (MRI) and explant pathology, and preoperative characteristics predictive of discordance are not well understood. Methods Patients who underwent orthotopic liver transplantation for HCC after preoperative MRI were identified in a prospectively collected institutional database (January 2003 to December 2013). Patients were dichotomized to "within" or "outside" Milan criteria by both imaging and explant pathologic evaluation. Binary logistic regression and Kaplan-Meier methodology were used to identify independent predictors of imaging/pathologic discordance and its impact on posttransplant survival. Results Of 318 patients with HCC meeting Milan criteria by MRI at the time of orthotopic liver transplantation, 248 (78.0%) remained within a pathological correlate of Milan criteria on explant examination. Understaging was associated with worse median recurrence-free survival (64.0 months vs 140.0 months, P = 0.002) and overall survival (96.0 months vs 143.0 months, P = 0.005), and did not vary between patients exceeding criteria due to tumor explant greater than 5 cm, more than 3 tumor foci, or a tumor greater than 3 cm in the setting of multifocality. Discordance was independently associated with an increasing serum alpha fetal protein level (odds ratio, 2.82; 95% confidence interval, 1.37-5.79; P = 0.005). Conclusions Underestimating HCC burden before liver transplant remains frequent despite contemporary imaging technologies. Patients with an increasing alpha fetal protein before transplantation may benefit from more frequent testing or novel neoadjuvant therapies.

Original languageEnglish (US)
Pages (from-to)648-655
Number of pages8
Issue number4
Publication statusPublished - Apr 1 2018
Externally publishedYes


ASJC Scopus subject areas

  • Transplantation

Cite this